Gastrointestinal Cancers (GI)
Cancer is the second leading cause of deaths worldwide. In 2022, around 33.3% of the mortality (i.e. 3.2 million deaths) were attributed by GI cancers. Common GI cancer types include colorectum, stomach, liver, pancreas and oesophagus.
Cadherin-17 (CDH17)
Dr. John Luk, the founder of Tiberias, and his team identified and patented CDH17 as a diagnostic marker for liver cancer. Subsequent RNASeq data and immunohistochemical (IHC) staining results revealed that CDH17 overexpression is not limited to liver cancer, but is also observed in other major GI cancers; suggesting the diagnostic potential of CDH17 in GI cancers.
CDH17 RNAseq Data (Source: The Cancer Genome Atlas)
Strong CDH17 Signal in Cancer Tissues Versus Adjacent Non-Tumour or Healthy Tissues (Source: In-house CDH17 IHC Staining Data)
Tiberias is now developing In-Vitro Diagnostic (IVD) platforms in 3 areas:
Immune staining (visualization) for CDH17 marker in clinical tissues
Ultra-sensitive measurement of circulating CA17 in high-throughput platform
